The Lung Cancer Partnering 2007-2013 provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
This data driven report contains over 200 links to online copies of actual lung cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of lung cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in lung cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading lung cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of lung cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of lung cancer technologies and products.
Lung Cancer Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to lung cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in lung cancer dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 200 lung cancer contract documents
- The leading lung cancer deals by value since 2007
In Lung Cancer Partnering 2007-2013, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 Introduction
Chapter 2 Trends in lung cancer partnering
2.2. Lung cancer partnering over the years
2.3. Bigpharma lung cancer dealmaking activity
2.4. Lung cancer partnering by deal type
2.5. Lung cancer partnering industry sector
2.6. Lung cancer partnering by stage of development
2.7. Lung cancer partnering by technology type
2.8. Disclosed financial deal terms for lung cancer partnering
2.8.1 Lung cancer headline values
2.8.2 Lung cancer upfront payments
2.8.3 Lung cancer milestone payments
2.8.4 Lung cancer royalty rates
Chapter 3 Leading lung cancer deals
3.2. Top lung cancer deals by value
3.3. Top lung cancer deals involving bigpharma
Chapter 4 Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form Reports
List of Chart
Figure 1: Lung cancer partnering since 2007
Figure 2: Bigpharma top 50 lung cancer deals 2007 to 2011
Figure 3: Bigpharma lung cancer deal frequency 2007 to 2011
Figure 4: Lung cancer partnering by deal type since 2007
Figure 5: Lung cancer partnering by industry sector since 2007
Figure 6: Lung cancer partnering by stage of development since 2007
Figure 7: Lung cancer partnering by technology type since 2007
Figure 8: Lung cancer deals with a headline value
Figure 9: Lung cancer deals with upfront payment values
Figure 10: Lung cancer deals with milestone payments
Figure 11: Lung cancer deals with royalty rates, %
Figure 12: Top lung cancer deals by value since 2007
Figure 13: Top lung cancer deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Make an enquiry before buying this Report
Please fill the enquiry form below.